Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 11/20 | 0.46 |
| ▸ | F13A1 | P00488 | 8/20 | 0.46 |
| ▸ | TGM1 | P22735 | 5/20 | 0.46 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726201 | 0.89 | MAPT (0.53) | MAPTPOLBTGM2F13A1TGM1 | |
| SCHEMBL6737197 | 0.87 | MAPT (0.48) | MAPTPOLBTGM2F13A1TGM1 | |
| SCHEMBL6730443 | 0.82 | PPARG (0.50) | MAPTPOLBTGM2F13A1TGM1 | |
| SCHEMBL6733950 | 0.79 | PPARG (0.47) | MAPTTGM2F13A1TGM1TGM3 | |
| SCHEMBL5202414 | 0.78 | STS (0.57) | MAPTPOLBTGM2F13A1TGM1 | |
| SCHEMBL29060789 | 0.77 | MAPT (0.73) | MAPTTGM2F13A1TGM1TGM3 | |
| SCHEMBL6731004 | 0.76 | LSS (0.52) | MAPTMEN1KMT2ATHRB | |
| SCHEMBL6729845 | 0.75 | F10 (0.48) | MAPTMEN1KMT2ATHRB | |
| SCHEMBL5253160 | 0.74 | POLB (0.70) | POLBTGM2F13A1TGM1STS | |
| SCHEMBL6729018 | 0.74 | F10 (0.60) | MAPTTGM2F13A1TGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | MAPT 4665/4885POLB 1782/4885TGM2 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.